Pinealon: limits of adverse-event evidence
Khavinson and colleagues studied synthetic pinealon, Glu-Asp-Arg, in cellular oxidative-stress models including PC12 cells. The 2011 abstract describes cellular measurements and provides no clinical adverse-event frequencies. [1]
This abstract cannot establish adverse reactions or human safety for pinealon. Changes in cell models do not establish risks for a particular reagent batch. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical adverse-event frequencies | Cellular oxidative-stress models, including PC12 cells | The abstract describes cellular measurements and provides no clinical adverse-event frequencies; it cannot establish adverse reactions or human safety for pinealon | [1] |
References
- Khavinson V et al. (2011). Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes https://doi.org/10.1089/rej.2011.1172.